share_log

Adaptimmune Therapeutics Q1 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $5.678M Miss $10.733M Estimate

Benzinga ·  May 15 08:00

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. The company reported quarterly sales of $5.678 million which missed the analyst consensus estimate of $10.733 million by 47.10 percent. This is a 88.07 percent decrease over sales of $47.601 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment